DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.

Two DNA vaccines were constructed encoding the ectodomain (domains I, II and III) of the DENV2 envelope protein (pE1D2) or only its domain III (pE2D2), fused to the human tissue plasminogen activator signal peptide (t-PA). The expression and secretion of recombinant proteins was confirmed in vitro i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Adriana S Azevedo, Anna M Y Yamamura, Marcos S Freire, Gisela F Trindade, Myrna Bonaldo, Ricardo Galler, Ada M B Alves
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2011
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b93119332faf4a7aa16d1ebb630c57ff
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b93119332faf4a7aa16d1ebb630c57ff
record_format	dspace
spelling	oai:doaj.org-article:b93119332faf4a7aa16d1ebb630c57ff2021-11-18T06:50:30ZDNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.1932-620310.1371/journal.pone.0020528https://doaj.org/article/b93119332faf4a7aa16d1ebb630c57ff2011-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21779317/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Two DNA vaccines were constructed encoding the ectodomain (domains I, II and III) of the DENV2 envelope protein (pE1D2) or only its domain III (pE2D2), fused to the human tissue plasminogen activator signal peptide (t-PA). The expression and secretion of recombinant proteins was confirmed in vitro in BHK cells transfected with the two plasmids, detected by immunofluorescence or immunoprecipitation of metabolically labeled gene products, using polyclonal and monoclonal antibodies against DENV2. Besides, results reveal that the ectodomain of the E protein can be efficiently expressed in vivo, in a mammalian system, without the prM protein that is hypothesized to act as a chaperonin during dengue infection. Balb/c mice were immunized with the DNA vaccines and challenged with a lethal dose of DENV2. All pE1D2-vaccinated mice survived challenge, while 45% of animals immunized with the pE2D2 died after infection. Furthermore, only 10% of pE1D2-immunized mice presented some clinical signs of infection after challenge, whereas most of animals inoculated with the pE2D2 showed effects of the disease with high morbidity degrees. Levels of neutralizing antibodies were significantly higher in pE1D2-vaccinated mice than in pE2D2-immunized animals, also suggesting that the pE1D2 vaccine was more protective than the pE2D2.Adriana S AzevedoAnna M Y YamamuraMarcos S FreireGisela F TrindadeMyrna BonaldoRicardo GallerAda M B AlvesPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 7, p e20528 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Adriana S Azevedo Anna M Y Yamamura Marcos S Freire Gisela F Trindade Myrna Bonaldo Ricardo Galler Ada M B Alves DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.
description	Two DNA vaccines were constructed encoding the ectodomain (domains I, II and III) of the DENV2 envelope protein (pE1D2) or only its domain III (pE2D2), fused to the human tissue plasminogen activator signal peptide (t-PA). The expression and secretion of recombinant proteins was confirmed in vitro in BHK cells transfected with the two plasmids, detected by immunofluorescence or immunoprecipitation of metabolically labeled gene products, using polyclonal and monoclonal antibodies against DENV2. Besides, results reveal that the ectodomain of the E protein can be efficiently expressed in vivo, in a mammalian system, without the prM protein that is hypothesized to act as a chaperonin during dengue infection. Balb/c mice were immunized with the DNA vaccines and challenged with a lethal dose of DENV2. All pE1D2-vaccinated mice survived challenge, while 45% of animals immunized with the pE2D2 died after infection. Furthermore, only 10% of pE1D2-immunized mice presented some clinical signs of infection after challenge, whereas most of animals inoculated with the pE2D2 showed effects of the disease with high morbidity degrees. Levels of neutralizing antibodies were significantly higher in pE1D2-vaccinated mice than in pE2D2-immunized animals, also suggesting that the pE1D2 vaccine was more protective than the pE2D2.
format	article
author	Adriana S Azevedo Anna M Y Yamamura Marcos S Freire Gisela F Trindade Myrna Bonaldo Ricardo Galler Ada M B Alves
author_facet	Adriana S Azevedo Anna M Y Yamamura Marcos S Freire Gisela F Trindade Myrna Bonaldo Ricardo Galler Ada M B Alves
author_sort	Adriana S Azevedo
title	DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.
title_short	DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.
title_full	DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.
title_fullStr	DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.
title_full_unstemmed	DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.
title_sort	dna vaccines against dengue virus type 2 based on truncate envelope protein or its domain iii.
publisher	Public Library of Science (PLoS)
publishDate	2011
url	https://doaj.org/article/b93119332faf4a7aa16d1ebb630c57ff
work_keys_str_mv	AT adrianasazevedo dnavaccinesagainstdenguevirustype2basedontruncateenvelopeproteinoritsdomainiii AT annamyyamamura dnavaccinesagainstdenguevirustype2basedontruncateenvelopeproteinoritsdomainiii AT marcossfreire dnavaccinesagainstdenguevirustype2basedontruncateenvelopeproteinoritsdomainiii AT giselaftrindade dnavaccinesagainstdenguevirustype2basedontruncateenvelopeproteinoritsdomainiii AT myrnabonaldo dnavaccinesagainstdenguevirustype2basedontruncateenvelopeproteinoritsdomainiii AT ricardogaller dnavaccinesagainstdenguevirustype2basedontruncateenvelopeproteinoritsdomainiii AT adambalves dnavaccinesagainstdenguevirustype2basedontruncateenvelopeproteinoritsdomainiii
_version_	1718424316065873920

DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.

Ejemplares similares